Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immunoprecise Antibodies Ltd - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
IPA
New York
2836
https://www.ipatherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
- Apr 12th, 2024 1:00 pm
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
- Mar 28th, 2024 11:02 am
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
- Mar 20th, 2024 11:02 am
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
- Mar 14th, 2024 12:05 pm
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
- Mar 8th, 2024 12:30 pm
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
- Mar 7th, 2024 12:02 pm
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
- Mar 4th, 2024 1:01 pm
ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery
- Feb 13th, 2024 1:35 pm
ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
- Jan 10th, 2024 2:00 pm
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call Transcript
- Dec 19th, 2023 1:18 pm
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
- Dec 14th, 2023 1:01 pm
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
- Dec 8th, 2023 10:00 pm
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
- Dec 7th, 2023 2:00 pm
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
- Dec 6th, 2023 12:00 pm
IPA Announces Proposed Public Offering of Common Shares
- Dec 5th, 2023 9:35 pm
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
- Nov 27th, 2023 1:01 pm
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery
- Nov 22nd, 2023 2:00 pm
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
- Nov 13th, 2023 1:32 pm
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
- Oct 25th, 2023 12:01 pm
IPA Provides Update on Growth Strategy and Recent Share Price Movement
- Oct 23rd, 2023 12:01 pm
Scroll